Can earlier Symphony thrombectomy accelerate heart recovery in intermediate-risk pulmonary embolism?
Find out how Imperative Care’s SYMPHONY-PE analysis could reshape thrombectomy timing in intermediate-risk pulmonary embolism.
Medical Devices & Diagnostics
Medical Devices & Diagnostics
Penumbra’s THUNDERBOLT clearance strengthens Boston Scientific’s pending vascular device bet
Find out how Penumbra’s THUNDERBOLT FDA clearance could reshape stroke thrombectomy, CAVT adoption, and medtech competition.
Medical Devices & Diagnostics
Why Rapid Medical’s DISTALS data could reshape treatment expectations in smaller stroke vessels
Distal stroke has long lacked device options. Rapid Medical’s TIGERTRIEVER 13 data now tests whether small-vessel thrombectomy can scale.
Medical Devices & Diagnostics
What Boston Scientific’s $14.5bn Penumbra buyout means for stroke and clot intervention markets
Boston Scientific Corporation has announced a definitive agreement to acquire Penumbra, Inc. for approximately $14.5 billion, marking one of its largest acquisitions to date in the medical device sector. The deal, structured as approximately 73 percent cash and 27 percent stock, offers Penumbra shareholders $374 per share and is expected to close in 2026, subject